Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Rating of “Moderate Buy” from Brokerages

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has been given a consensus recommendation of “Moderate Buy” by the five research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $5.80.

A number of research firms have recently weighed in on SGMO. Jefferies Financial Group reduced their target price on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday, December 31st. StockNews.com downgraded shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Wells Fargo & Company reduced their target price on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating on the stock in a report on Tuesday, December 31st. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Sangamo Therapeutics in a research note on Monday, January 27th. Finally, Truist Financial dropped their price target on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, January 23rd.

Sangamo Therapeutics Stock Up 6.2 %

Sangamo Therapeutics stock opened at $0.98 on Friday. The company’s 50-day moving average price is $1.10 and its 200-day moving average price is $1.40. Sangamo Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.18. The company has a market cap of $204.72 million, a PE ratio of -1.31 and a beta of 1.49.

Institutional Investors Weigh In On Sangamo Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. LPL Financial LLC boosted its position in Sangamo Therapeutics by 113.5% in the 4th quarter. LPL Financial LLC now owns 31,031 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 16,498 shares during the period. Northern Trust Corp boosted its position in Sangamo Therapeutics by 4.5% in the 4th quarter. Northern Trust Corp now owns 398,289 shares of the biopharmaceutical company’s stock valued at $406,000 after buying an additional 17,049 shares during the period. JPMorgan Chase & Co. boosted its position in Sangamo Therapeutics by 679.5% in the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 21,793 shares during the period. E Fund Management Co. Ltd. purchased a new stake in Sangamo Therapeutics in the 4th quarter valued at about $25,000. Finally, PNC Financial Services Group Inc. boosted its position in Sangamo Therapeutics by 2,319.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 25,000 shares during the period. 56.93% of the stock is owned by hedge funds and other institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.